BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12934099)

  • 41. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.
    Galkin AV; Melnick JS; Kim S; Hood TL; Li N; Li L; Xia G; Steensma R; Chopiuk G; Jiang J; Wan Y; Ding P; Liu Y; Sun F; Schultz PG; Gray NS; Warmuth M
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):270-5. PubMed ID: 17185414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
    Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
    Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.
    Kiss I; Unger C; Huu CN; Atanasov AG; Kramer N; Chatruphonprasert W; Brenner S; McKinnon R; Peschel A; Vasas A; Lajter I; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
    Cancer Lett; 2015 Jan; 356(2 Pt B):994-1006. PubMed ID: 25444930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells.
    Huang JS; Guh JY; Hung WC; Yang ML; Lai YH; Chen HC; Chuang LY
    Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):231-8. PubMed ID: 10432321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
    Turturro F; Arnold MD; Frist AY; Pulford K
    Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.
    Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C
    Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.
    Piva R; Pellegrino E; Mattioli M; Agnelli L; Lombardi L; Boccalatte F; Costa G; Ruggeri BA; Cheng M; Chiarle R; Palestro G; Neri A; Inghirami G
    J Clin Invest; 2006 Dec; 116(12):3171-82. PubMed ID: 17111047
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Caspase-3 activation in systemic anaplastic large-cell lymphoma.
    Drakos E; Rassidakis GZ; Lai R; Herling M; O'Connor SL; Schmitt-Graeff A; McDonnell TJ; Medeiros LJ
    Mod Pathol; 2004 Jan; 17(1):109-16. PubMed ID: 14657946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. JAK/STAT pathway plays a critical role in the proinflammatory gene expression and apoptosis of RAW264.7 cells induced by trichothecenes as DON and T-2 toxin.
    Wang X; Liu Q; Ihsan A; Huang L; Dai M; Hao H; Cheng G; Liu Z; Wang Y; Yuan Z
    Toxicol Sci; 2012 Jun; 127(2):412-24. PubMed ID: 22454431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
    Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
    Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
    Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas.
    Thompson MA; Stumph J; Henrickson SE; Rosenwald A; Wang Q; Olson S; Brandt SJ; Roberts J; Zhang X; Shyr Y; Kinney MC
    Hum Pathol; 2005 May; 36(5):494-504. PubMed ID: 15948116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells.
    Burke WM; Jin X; Lin HJ; Huang M; Liu R; Reynolds RK; Lin J
    Oncogene; 2001 Nov; 20(55):7925-34. PubMed ID: 11753675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulation of IL-6-induced STAT3 tyrosine phosphorylation by TGF-beta1 is mediated by caspase-dependent and -independent processes.
    Wierenga AT; Schuringa JJ; Eggen BJ; Kruijer W; Vellenga E
    Leukemia; 2002 Apr; 16(4):675-82. PubMed ID: 11960349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-6-resistant melanoma cells exhibit reduced activation of STAT3 and lack of inhibition of cyclin E-associated kinase activity.
    Böhm M; Schulte U; Funk JO; Raghunath M; Behrmann I; Kortylewski M; Heinrich PC; Kues T; Luger TA; Schwarz T
    J Invest Dermatol; 2001 Jul; 117(1):132-40. PubMed ID: 11442760
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
    Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling.
    Honorat JF; Ragab A; Lamant L; Delsol G; Ragab-Thomas J
    Blood; 2006 May; 107(10):4130-8. PubMed ID: 16469875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repair.
    Bone KM; Wang P; Wu F; Wu C; Li L; Bacani JT; Andrew SE; Lai R
    Blood Cancer J; 2015 May; 5(5):e311. PubMed ID: 25978431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Inhibition of constitutively activated Jak3 and induction of apoptosis in NALM-6 cell line].
    Hu W; Zhang C; Zhang P; Wei D; Zhao Z; Cai M
    Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):25-7. PubMed ID: 12599420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.